Last updated: 11/07/2018 07:49:45
Assessment of the serologic response to Porcine circovirus type 1 (PCV-1) in the serum of infants and toddlers, following administration of IPV (Inactivated poliovirus vaccine)-containing vaccines
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Finalized
Finalized
Trial overview
Official title: Blinded retrospective laboratory evaluations to assess the serologic response to Porcine circovirus type 1 (PCV-1) in the serum of infants aged 2 and 6 months and toddlers aged 4-6 years following administration of GlaxoSmithKline (GSK) Biologicals’ IPV-containing vaccines
Trial description: This study aims to analyse the serologic response to PCV-1 in the PEDIARIX® [GSK Biologicals’ Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine] and KINRIX® (GSK Biologicals’ Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine) vaccine products. The samples have been collected at pre-determined time points from a subset of subjects who participated in selected studies [217744/085 and 213503/048] conducted in the United States.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Presence of serum anti-PCV-1 antibody.
Timeframe: At Day 0 and post vaccination time points (up to 1 month after vaccination).
Secondary outcomes:
Not applicable
Interventions:
Procedure/surgery: Serum sample
Enrollment:
1
Observational study model:
Other
Primary completion date:
Not applicable
Time perspective:
Retrospective
Clinical publications:
Dubin G et al. (2013) Investigation of a regulatory agency enquiry into potential porcine circovirus type 1 contamination of the human rotavirus vaccine, Rotarix™: approach and outcome. Hum Vaccin Immunother. 28;9(11). [Epub ahead of print].
Medical condition
Presence of materials from PCV-1
Product
SB217744
Collaborators
Not applicable
Study date(s)
May 2010 to May 2010
Type
Observational
Phase
Not applicable
Participation criteria
Sex
Female & Male
Age
2 months - 6 years
Accepts healthy volunteers
Yes
- Subjects enrolled previously in randomized, open and multicentre studies [217744/085; 213503/048].
- Subjects aged 6 months to 6 years at last dose vaccinated with either DTaP-HepB-IPV vaccine or separately administered DTaP, HepB, and IPV vaccines or DTaP-IPV vaccine or separately administered DTaP and IPV vaccines.
- Not Applicable
Inclusion and exclusion criteria
Inclusion criteria:
- Subjects aged 6 months to 6 years at last dose vaccinated with either DTaP-HepB-IPV vaccine or separately administered DTaP, HepB, and IPV vaccines or DTaP-IPV vaccine or separately administered DTaP and IPV vaccines.
- Subjects for whom sufficient residual volume of the pre and post vaccination blood samples is available.
Subjects enrolled previously in randomized, open and multicentre studies [217744/085; 213503/048].
Exclusion criteria:
- Not Applicable
Trial location(s)
No location data available.
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Finalized
Actual primary completion date
Not applicable
Actual study completion date
2010-25-05
Plain language summaries
Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website